Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Innovative Solutions Opening (ISO)

SOL #: ARPA-H-SOL-26-142Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Washington, DC, 20005, United States

Place of Performance

Washington, DC

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

Health R&D Services; Health Care Services; Experimental Development (AN13)

Set Aside

No set aside specified

Timeline

1
Posted
Jan 12, 2026
2
Last Updated
Feb 23, 2026
3
Submission Deadline
Apr 1, 2026, 9:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Advanced Research Projects Agency for Health (ARPA-H), under the National Institutes of Health (NIH), has issued an Innovative Solutions Opening (ISO) for the Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program. This solicitation seeks innovative solutions to develop an Agentic AI system for autonomous and semi-autonomous clinical care for patients with cardiovascular disease (CVD). The program aims to modernize CVD care management by addressing technical and structural barriers, supporting regulatory pathways, and facilitating clinical deployment. Proposals are due April 1, 2026.

Scope of Work

The ADVOCATE program focuses on three technical areas (TAs):

  • TA1 (CVD Agent): Develop a clinically validated, regulatory-compliant, patient-facing AI agent for care management, capable of diagnostic reasoning, treatment recommendations, and integration with EHRs and wearables.
  • TA2 (Supervisory Agent): Create a disease-agnostic agent for continuous monitoring, auditability, and regulatory compliance of clinical agents, assessing risk and accuracy.
  • TA3 (Scaled Implementation): Integrate CVD and Supervisory agents into healthcare settings, conduct scalability studies, and evaluate cost-efficiency and safety. The program is structured in two phases over 39 months, with down-selection points at 12 and 24 months.

Contract Details

ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements. The period of performance is 39 months, divided into Phase 1A (12 months), Phase 1B (12 months), and Phase 2 (15 months). Resource sharing is highly encouraged, with cash contributions preferred. There is no set-aside designation for this opportunity.

Eligibility & Restrictions

Eligible proposers include universities, non-profit organizations, small businesses, other than small businesses, and non-federal research centers. Federal Funded Research and Development Centers (FFRDCs) and government entities are prohibited from participating as prime or sub-performers. Individuals providing contracted support services to ARPA-H are ineligible due to Organizational Conflicts of Interest (OCI). Proposers for TA3 cannot submit proposals for TA1 or TA2 in any capacity.

Submission & Evaluation

Submissions require a Solution Summary followed by a Full Proposal, both submitted via the ARPA-H Solution Submission Portal. Proposals will be evaluated based on four criteria in descending order of importance: 1) Overall Scientific and Technical Merit, 2) Proposer's Capabilities and/or Related Experience, 3) Potential Contribution to Relevance to the ARPA-H Mission and User Experience, and 4) Assessment of Proposed Cost/Price.

  • Solution Summary Due Date: February 27, 2026
  • Full Proposal Due Date: April 1, 2026

Amendments

This solicitation has been amended twice. Amendment 01 (February 5, 2026) corrected performer collaboration expectations, revised restrictions for TA3 proposers (preventing them from submitting for TA1/TA2), and updated OCI disclosure requirements. Amendment 02 (February 23, 2026) further revised sections including the Table of Contents, TA1 description, Phase 2 timeline, submission information, solution summary review process, full proposal evaluation criteria (Criteria 1), and handling of sensitive information. Bidders must review both amendments for complete and accurate submission guidance.

Attachments

Key attachments include cost proposal spreadsheets (for OTs with and without resource sharing), a cost proposal narrative template, and a sample OT Agreement, which outlines standard terms for intellectual property rights and data management.

People

Points of Contact

SEE DESCRIPTION SECTIONPRIMARY

Files

Files

Download
Download
Download
Download
Download
Download
Download
Download

Versions

Version 3Viewing
Solicitation
Posted: Feb 23, 2026
Version 2
Solicitation
Posted: Feb 5, 2026
View
Version 1
Solicitation
Posted: Jan 12, 2026
View
Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Innovative Solutions Opening (ISO) | GovScope